Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR5A | P47898 | 1/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9119766 | 0.78 | ALDH1A1 (0.37) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL9121582 | 0.73 | HTR7 (0.47) | HTR6HTR7HTR1AHTR2AHTR2B | |
| SCHEMBL9119974 | 0.73 | ADRB1 (0.44) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL9119858 | 0.72 | HTR7 (0.51) | HTR7HTR1AADRB1 | |
| SCHEMBL9119904 | 0.71 | HTR6 (0.46) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL9119128 | 0.71 | HTR1A (0.43) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL9119205 | 0.71 | ADRB1 (0.49) | HTR6HTR7HTR1AHTR2AHTR5A | |
| SCHEMBL5029237 | 0.71 | ADRB1 (0.47) | ADRB1 | |
| SCHEMBL2876202 | 0.70 | ADRB1 (0.52) | HTR6HTR7HTR1AHTR5AADRB1 | |
| SCHEMBL2934400 | 0.69 | KCNH2 (0.40) | HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0189612-B1 | NEW PHARMACEUTICAL COMPOSITIONS HAVING A PSYCHOTROPIC ACTIVITY | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1992-11-04 | — | — | EP | claimed |
| EP-2563790-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2563791-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| EP-2563791-A1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2013-03-06 | — | — | EP | disclosed |
| WO-2000040554-A1 | ARYLPIPERAZINYL-CYCLOHEXYL INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-07-13 | — | — | WO | disclosed |
| CN-1049654-C | Piperazine derivatives | DAIICHI SEIYAKU CO (JP) | 2000-02-23 | — | — | CN | disclosed |
| EP-0624584-B1 | Piperazine derivatives useful as calmodulin inhibitors | DAIICHI SEIYAKU CO (JP) | 1998-08-19 | — | — | EP | disclosed |
| US-5681954-A | HAS CALMODULIN INHIBITORY ACTIVITY; USEFUL IN TREATING DISEASES OF THE CIRCULATORY ORGANS OR IN CEREBRAL REGION | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-28 | — | — | US | disclosed |
| US-5605896-A | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-02-25 | — | — | US | disclosed |
| US-5424313-A | Bibyclic heteroacrylpiperazine derivatives having psychotropic activity, and pharmaceutical compositions containing these derivatives | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1995-06-13 | — | — | US | disclosed |
| EP-0624584-A1 | Piperazine derivatives useful as calmodolin inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-11-17 | — | — | EP | disclosed |
| US-4833142-A | Blood-pressure lowering 4-bicyclic-1-piperazinyl-alkyl amides | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 1989-05-23 | — | — | US | disclosed |
| EP-0138280-B1 | BLOOD-PRESSURE LOWERING PIPERAZINE DERIVATIVES | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1988-06-08 | — | — | EP | disclosed |
| EP-0138280-A2 | Blood-pressure lowering piperazine derivatives | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | HTR6 4122/4885HTR7 3926/4885HTR1A 4433/4885 |
| US-20140031548-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | HTR6 4469/4885HTR7 4466/4885HTR1A 4680/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | HTR6 4372/4885HTR7 4314/4885HTR1A 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.